TITLE:
MK0653A (Ezetimibe (+) Simvastatin) Compared to an Approved Drug (Atorvastatin) for the Treatment of High Cholesterol (0653A-051)(COMPLETED)

CONDITION:
Hypercholesterolemia

INTERVENTION:
MK0653A, ezetimibe (+) simvastatin

SUMMARY:

      This study is to assess the safety and efficacy of an investigational drug as compared to an
      approved drug to reduce specific cholesterol levels.
    

DETAILED DESCRIPTION:

      The duration of treatment is 6 weeks.
    

ELIGIBILITY:
Gender: All
Age: 18 Years to 79 Years
Criteria:

        Inclusion Criteria:

          -  Elevated cholesterol

        Exclusion Criteria:

          -  Unstable medical conditions or significant heart problems within 3 months prior to
             first study visit.
      
